Which one has less side effects and is more effective, eltrombopag or heltrombopag?

Eltrombopag and eltrombopag are both thrombopoietin receptor agonists used to treat thrombocytopenia.

Common side effects of eltrombopag include headache, anemia, loss of appetite, insomnia, etc. In addition, symptoms such as nausea, cough, diarrhea, hair loss, itching, myalgia, fever, and influenza-like illness may also occur. These side effects may affect the patient's quality of life to some extent. The side effects of Hetrombopag are relatively small, but long-term and large-scale use may also cause nausea, skin itching, insomnia and other adverse reactions. It should be noted that Hetrombopag has relatively few side effects on liver function, which has been verified in some clinical trials and patient feedback.

Eltrombopag stimulates the proliferation and differentiation of megakaryocytes and increases the number of platelets in the circulation, thereby improving hemostatic function, shortening coagulation time, and promoting the recovery of bone marrow hematopoietic function. It is suitable for the treatment of thrombocytopenia caused by various causes, such as macroglobulinemia, aplastic anemia, etc. Hetrombopag also promotes platelet production by stimulating the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells. It is mainly used to treat idiopathic thrombocytopenic purpura, helping to control the condition, reduce platelet transfusion, and reduce the risk of blood transfusion.

Therefore, when choosing which drug to use, a comprehensive consideration should be based on the patient's specific illness, physical condition, and doctor's recommendations. At the same time, no matter which drug is used, indicators such as platelet count and liver and kidney function should be regularly monitored to ensure the safety and effectiveness of the drug.